journal article·2024-11Open access

Self‐Assembly Hypoxic and ROS Dual Response Nano Prodrug as a New Therapeutic Approach for Glaucoma Treatments

Xuezhi Zhou, Rong Rong, Ganghao Liang, Yukun Wu, Chun Xu, Haihua Xiao, Dan Ji, Xiaobo Xia

Advanced Science· Volume 11· Issue 41

Abstract

Abstract Glaucoma is an irreversible blinding eye disease characterized by retinal ganglion cell (RGC) death.Previous studies have demonstrated that protecting mitochondria and activating the CaMKII/CREB signaling pathway can effectively protect RGC and axon. However, currently treatments are often unsatisfactory, and the pathogenesis of glaucoma requires further elucidation. In this study, a ROS‐responsive dual drug conjugate (OLN monomer) is first designed that simultaneously bonds nicotinamide and oleic acid. The conjugate self‐assembled into nanoparticles (uhOLN‐NPs) through the aggregation of multiple micelles and possesses ROS scavenging capability. Then, a polymer with a hypoxic response function is designed, which encapsulates uhOLN‐NPs to form nanoparticles with hypoxic and ROS responses (HOLN‐NPs). Under hypoxia in RGCs, the azo bond of HOLN‐NPs breaks and releases uhOLN‐NPs. Meanwhile, under high ROS conditions, the thioketone bond broke, leading to the dissociation of nano‐prodrug. The released nicotinamide and oleic acid co‐scavenge ROS and activate the CaMKII/CREB pathway, protecting mitochondria in RGCs. HOLN‐NPs exhibit a significantly superior protective effect on R28 cells in glutamate models of glaucoma. The accumulation of HOLN‐NPs in retinal RGCs lead to significant inhibition of RGC apoptosis and axonal damage in vivo. Notably, HOLN‐NPs provide a new therapeutic approach for patients with neurodegenerative disease.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Glaucoma and retinal disorders · Retinal Diseases and Treatments · Proteoglycans and glycosaminoglycans research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Ophthalmology Xiangya Hospital, Central South University Changsha Hunan 410008 P. R. China

Hunan Key Laboratory of Ophthalmology Changsha Hunan 410008 P. R. China

National Clinical Research Center for Geriatric Diseases Central South University Changsha Hunan 410008 P. R. China

Beijing National Laboratory for Molecular Sciences State Key Laboratory of Polymer Physics Institute of Chemistry Chinese Academy of Sciences Beijing 100190 P. R. China

University of Chinese Academy of Sciences Beijing 100049 P. R. China

School of Dentistry The University of Queensland Brisbane 4006 Australia

Funding

National Natural Science Foundation of China · National Key Research and Development Program of China

References (39)

Show source-provided references
1. 10.1016/j.ophtha.2014.05.01310.1016/j.ophtha.2014.05.013 ↗
2. 10.1016/j.addr.2023.11478110.1016/j.addr.2023.114781 ↗
3. 10.1038/s41591-022-01862-810.1038/s41591-022-01862-8 ↗
4. 10.1016/j.preteyeres.2022.10116110.1016/j.preteyeres.2022.101161 ↗
5. 10.1016/j.preteyeres.2022.10113610.1016/j.preteyeres.2022.101136 ↗
6. 10.1016/j.preteyeres.2020.10090110.1016/j.preteyeres.2020.100901 ↗
7. 10.1016/j.preteyeres.2021.10095310.1016/j.preteyeres.2021.100953 ↗
8. 10.1038/s41580-021-00433-y10.1038/s41580-021-00433-y ↗
9. 10.1038/s41586-022-04979-510.1038/s41586-022-04979-5 ↗
10. 10.1016/j.redox.2022.10254110.1016/j.redox.2022.102541 ↗
11. 10.1016/j.redox.2023.10268710.1016/j.redox.2023.102687 ↗
12. 10.1002/adma.20220014610.1002/adma.202200146 ↗
13. 10.1021/acs.accounts.1c0044310.1021/acs.accounts.1c00443 ↗
14. 10.1002/adma.20220620010.1002/adma.202206200 ↗
15. 10.1039/C9CS00283A10.1039/C9CS00283A ↗
16. 10.1002/advs.20220061510.1002/advs.202200615 ↗
17. 10.1016/j.cell.2021.06.03110.1016/j.cell.2021.06.031 ↗
18. 10.1016/j.cmet.2022.02.00110.1016/j.cmet.2022.02.001 ↗
19. 10.1126/scitranslmed.abd706410.1126/scitranslmed.abd7064 ↗
20. 10.1073/pnas.201122611810.1073/pnas.2011226118 ↗
21. 10.1016/j.cmet.2022.11.00410.1016/j.cmet.2022.11.004 ↗
22. 10.1016/j.cell.2021.07.00510.1016/j.cell.2021.07.005 ↗
23. 10.1016/j.ymthe.2022.01.03510.1016/j.ymthe.2022.01.035 ↗
24. 10.1002/advs.20220682010.1002/advs.202206820 ↗
25. 10.1016/j.lfs.2014.07.01310.1016/j.lfs.2014.07.013 ↗
26. 10.1136/gutjnl-2020-32177410.1136/gutjnl-2020-321774 ↗
27. 10.1016/j.molmed.2021.07.00710.1016/j.molmed.2021.07.007 ↗
28. 10.1002/anie.20230147610.1002/anie.202301476 ↗
29. 10.1016/j.redox.2022.10234010.1016/j.redox.2022.102340 ↗
30. 10.1038/s41392-020-00354-w10.1038/s41392-020-00354-w ↗
31. 10.1016/j.tcb.2023.02.00410.1016/j.tcb.2023.02.004 ↗
32. 10.1038/s41419-021-03926-y10.1038/s41419-021-03926-y ↗
33. 10.1016/j.neuron.2022.06.00310.1016/j.neuron.2022.06.003 ↗
34. 10.1016/j.neuron.2022.06.00210.1016/j.neuron.2022.06.002 ↗
35. 10.1038/s41467-023-37737-w10.1038/s41467-023-37737-w ↗
36. 10.1038/s41467-021-22278-x10.1038/s41467-021-22278-x ↗
37. 10.1016/j.preteyeres.2020.10091610.1016/j.preteyeres.2020.100916 ↗
38. 10.1016/j.redox.2021.10198810.1016/j.redox.2021.101988 ↗
39. 10.1016/j.preteyeres.2021.10099810.1016/j.preteyeres.2021.100998 ↗